Trilliome is developing a proprietary AI and human gut model platform capable of identifying molecular combinations that reprogram the microbiome — boosting keystone bacterial species and restoring functions linked to brain and immune health.
Trilliome has raised €50k across 1 funding round from 1 investor, most recently a round in Oct 2025. Based in Zurich, Switzerland; active in Healthtech. Data as of 7 Aug 2026.
Timing: in window vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2025-10-28 | Other | €50k |
| EIT Food Accelerator Network’s “Food as Medicine” programme |
| View deal → |
